Impact of non-alcoholic hepatic steatosis on prognosis and clinical outcomes in gastric cancer patients undergoing laparoscopic distal gastrectomy

Table 3 Univariable Cox regression model for overall survival and progression-free survival in the propensity score-matched samples

Variables	Overall survival		Progression-free survival
	HR (95%CI)	P value	HR (95%CI)	P value
NAFLD yes vs no	0.60 (0.13-2.64)	0.496	2.56 (1.16-5.64)	0.02a
FIB-4 score	1.52 (1.02-2.31)	0.04a	1.31 (0.91-1.89)	0.144
Age	1.07 (1.02-1.12)	0.007a	1.06 (1.02-1.09)	0.003a
Sex Male vs Female	0.39 (0.14-1.08)	0.07	0.36 (0.16-0.80)	0.001a
BMI	0.90 (0.76-1.06)	0.21	1.07 (0.96-1.2)	0.223
T stage T1-T2 vs T3-4	0.05 (0.01-0.21)	6.71 × 10-5a	0.07 (0.03-0.18)	7.47 × 10-8a
N stage N0-1 vs N2-3	0.08 (0.03-0.25)	1.53 × 10-5a	0.10 (0.05-0.23)	4.29 × 10-8a
Stage I-II vs III	0.06 (0.02-0.20)	2.6 × 10-6a	0.08 (0.04-0.18)	1.37 × 10-9a
Vascular invasion yes vs no	4.2 (1.52-11.6)	0.006	2.3 (1.05-5.08)	0.038
Neural invasion yes vs no	5.94 (2.11-16.7)	7.23 × 10-4a	4.08 (1.89-8.81)	3.44 × 10-4a
Total retrieved lymph node	1.00 (0.96-1.04)	0.852	0.99 (0.96-1.02)	0.529
Positive lymph node	1.11 (1.07-1.14)	5.28 × 10-10a	1.10 (1.07-1.13)	9.73 × 10-13a
Positive lymph node rate	2.86 (1.88-4.36)	9.01 × 10-7a	2.56 (1.9-3.45)	6.98 × 10-10a

^aP < 0.05, statistically significant.

NAFLD: Non-alcoholic fatty liver disease; BMI: Body mass index.